8-K: Biotricity Secures $1 Million in Private Placement, With Potential for Additional Funding

Biotricity Inc. has entered into a securities purchase agreement for a private placement of convertible preferred stock, raising an initial $1 million with a potential for an additional $1 million.

Summary

• Biotricity Inc. has secured a $1 million investment through a private placement with an institutional investor.
• The company issued 110 shares of Series B Convertible Preferred Stock at $9,090.91 per share.
• There is an option for a second closing within 30 days, which would bring in an additional $1 million through the sale of another 110 shares at the same price.
• Biotricity is required to seek stockholder approval for the conversion of the Series B Preferred Stock if required by Nasdaq rules.
• The company has agreed to hold a stockholder meeting within 75 days of when two conversions would require approval, and every three months thereafter until approval is obtained.
• A registration rights agreement is in place, requiring the company to file a registration statement with the SEC within 45 days for the initial closing and 10 days after the second closing.
• The company is obligated to issue 100,000 shares of common stock to the investor if it fails to meet the deadlines for filing the registration statement or having it declared effective.
• The Series B Preferred Stock has a stated value of $10,000 per share and ranks senior to all other capital stock unless a majority of holders agree otherwise.
• Holders of the Series B Preferred Stock are entitled to cumulative dividends at an annual rate of 8%, increasing to 15% upon a triggering event.
• The initial conversion price for the preferred stock is $3.50 per share, subject to adjustments.
• The maximum number of common shares issuable upon conversion is estimated to be 1,142,342, assuming the second closing option is exercised.
• Holders can elect to convert at an alternate price equal to 80% (or 70% under certain conditions) of the lowest daily volume weighted average price of the common stock.
• The company has the option to pay cash equal to 110% of the conversion amount instead of issuing shares at the alternate conversion price.
• The Series B Preferred Stock will automatically convert to common stock after 24 months.
• Holders can require the company to redeem their shares upon a triggering event or a bankruptcy triggering event.
• The company has the right to redeem the preferred stock at 110% of the stated value plus any accrued dividends.
• Holders of the Series B Preferred Stock have voting rights on an as-converted basis.
• Certain stockholders have entered into a voting agreement to vote in favor of the Stockholder Approval and against any action that would breach the purchase agreement.

Sentiment

Score: 7

Explanation: The document indicates a positive development for Biotricity, securing a significant capital infusion. However, the potential for dilution and the obligations related to registration and stockholder approval temper the overall sentiment.

Positives

• The private placement provides Biotricity with a significant capital infusion of $1 million, with the potential for an additional $1 million.
• The terms of the Series B Preferred Stock include a dividend, which could be attractive to investors.
• The conversion feature of the preferred stock allows investors to participate in the potential upside of the company's common stock.
• The company has the option to pay cash instead of issuing shares at the alternate conversion price, which could be beneficial in certain situations.
• The voting agreement ensures that key stockholders will support the necessary approvals for the conversion of the preferred stock.

Negatives

• The company is obligated to issue 100,000 shares of common stock to the investor if it fails to meet certain deadlines related to the registration statement, which could dilute existing shareholders.
• The conversion of the preferred stock could significantly dilute the existing common stock, with a maximum of 1,142,342 shares potentially being issued.
• The alternate conversion price could result in a lower conversion price for the investor, further increasing dilution.
• The company is required to hold multiple stockholder meetings to obtain approval for the conversion, which could be costly and time-consuming.

Risks

• Failure to meet the deadlines for filing the registration statement or having it declared effective could result in the issuance of additional shares to the investor.
• The conversion of the preferred stock could significantly dilute the existing common stock, potentially impacting the share price.
• The alternate conversion price could result in a lower conversion price for the investor, further increasing dilution.
• The company may face challenges in obtaining the necessary stockholder approvals for the conversion of the preferred stock.
• The company may be required to redeem the preferred stock under certain triggering events, which could strain its finances.

Future Outlook

The company has the option to require the investor to purchase an additional 110 shares of Series B Preferred Stock within 30 days, potentially doubling the investment. The company is also required to seek stockholder approval for the conversion of the preferred stock, which will be a key step in the future.

Industry Context

Private placements are a common method for companies to raise capital, particularly for smaller or growth-stage companies. The use of convertible preferred stock is also a common structure, as it provides investors with downside protection while allowing them to participate in the potential upside of the company's common stock. The need for shareholder approval for conversion is a standard requirement for companies listed on exchanges like Nasdaq.

Comparison to Industry Standards

• The terms of this private placement, including the dividend rate and conversion features, are generally consistent with industry standards for similar transactions.
• The use of an alternate conversion price based on the market price of the common stock is a common feature in convertible securities, designed to protect investors from significant declines in the stock price.
• The requirement for shareholder approval for the conversion of preferred stock is a standard practice for companies listed on exchanges like Nasdaq, as it ensures that existing shareholders have a say in the potential dilution of their ownership.
• The penalties for failing to meet registration deadlines, such as the issuance of additional shares, are also common in these types of agreements, designed to incentivize the company to comply with its obligations.

Stakeholder Impact

• Shareholders may experience dilution if the preferred stock is converted to common stock.
• The capital raise could provide the company with resources to pursue its business objectives, potentially benefiting employees and customers.
• The company's creditors may be impacted by the terms of the preferred stock, which ranks senior to other capital stock.

Next Steps

• The company will need to file a registration statement with the SEC within 45 days for the initial closing and 10 days after the second closing.
• The company will need to hold a stockholder meeting to obtain approval for the conversion of the preferred stock.
• The investor may exercise its option to purchase an additional 110 shares of Series B Preferred Stock within 30 days.

Key Dates

Keywords

private placement, convertible preferred stock, Series B Preferred Stock, registration rights, stockholder approval, dilution, conversion price, voting agreement, capital raise, institutional investor